Jae-Hyeon Jeong, Dae-Joon Kim, Seong-Jin Hong, Jae-Hee Ahn, Dong-Ju Lee, Ah-Ra Jang, Sungyun Kim, Hyun-Jong Cho, Jae-Young Lee, Jong-Hwan Park, Young-Min Kim, Hyun-Jeong Ko
{"title":"研究 Aureobasidium pullulans β-葡聚糖在癌症免疫疗法中的免疫刺激潜力","authors":"Jae-Hyeon Jeong, Dae-Joon Kim, Seong-Jin Hong, Jae-Hee Ahn, Dong-Ju Lee, Ah-Ra Jang, Sungyun Kim, Hyun-Jong Cho, Jae-Young Lee, Jong-Hwan Park, Young-Min Kim, Hyun-Jeong Ko","doi":"10.4062/biomolther.2024.047","DOIUrl":null,"url":null,"abstract":"<p><p>β-glucan, a polysaccharide found in various sources, exhibits unique physicochemical properties, yet its high polymerization limits clinical applications because of its solubility. Addressing this limitation, we introduce PPTEE-glycan, a highly purified soluble β-1,3/1,6-glucan derived from <i>Aureobasidium pullulans</i>. The refined PPTEE-glycan demonstrated robust immune stimulation <i>in vitro</i>, activated dendritic cells, and enhanced co-stimulatory markers, cytokines, and cross-presentation. Formulated as a PPTEE + microemulsion (ME), it elevated immune responses <i>in vivo</i>, promoting antigen-specific antibodies and CD8+ T cell proliferation. Intratumoral administration of PPTEE + ME in tumor-bearing mice induced notable tumor regression, which was linked to the activation of immunosuppressive cells. This study highlights the potential of high-purity <i>Aureobasidium pullulans</i>-derived β-glucan, particularly PPTEE, as promising immune adjuvants, offering novel avenues for advancing cancer immunotherapy.</p>","PeriodicalId":8949,"journal":{"name":"Biomolecules & Therapeutics","volume":" ","pages":"556-567"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392664/pdf/","citationCount":"0","resultStr":"{\"title\":\"Investigating the Immune-Stimulating Potential of β-Glucan from <i>Aureobasidium pullulans</i> in Cancer Immunotherapy.\",\"authors\":\"Jae-Hyeon Jeong, Dae-Joon Kim, Seong-Jin Hong, Jae-Hee Ahn, Dong-Ju Lee, Ah-Ra Jang, Sungyun Kim, Hyun-Jong Cho, Jae-Young Lee, Jong-Hwan Park, Young-Min Kim, Hyun-Jeong Ko\",\"doi\":\"10.4062/biomolther.2024.047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>β-glucan, a polysaccharide found in various sources, exhibits unique physicochemical properties, yet its high polymerization limits clinical applications because of its solubility. Addressing this limitation, we introduce PPTEE-glycan, a highly purified soluble β-1,3/1,6-glucan derived from <i>Aureobasidium pullulans</i>. The refined PPTEE-glycan demonstrated robust immune stimulation <i>in vitro</i>, activated dendritic cells, and enhanced co-stimulatory markers, cytokines, and cross-presentation. Formulated as a PPTEE + microemulsion (ME), it elevated immune responses <i>in vivo</i>, promoting antigen-specific antibodies and CD8+ T cell proliferation. Intratumoral administration of PPTEE + ME in tumor-bearing mice induced notable tumor regression, which was linked to the activation of immunosuppressive cells. This study highlights the potential of high-purity <i>Aureobasidium pullulans</i>-derived β-glucan, particularly PPTEE, as promising immune adjuvants, offering novel avenues for advancing cancer immunotherapy.</p>\",\"PeriodicalId\":8949,\"journal\":{\"name\":\"Biomolecules & Therapeutics\",\"volume\":\" \",\"pages\":\"556-567\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392664/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomolecules & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4062/biomolther.2024.047\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecules & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4062/biomolther.2024.047","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
β-葡聚糖是一种存在于各种来源的多糖,具有独特的物理化学特性,但由于其可溶性,其高度聚合性限制了临床应用。针对这一局限性,我们推出了 PPTEE-聚糖,一种高度纯化的可溶性 β-1,3/1,6-聚糖,提取自 Aureobasidium pullulans。精制的 PPTEE-葡聚糖在体外显示出强大的免疫刺激作用,可激活树突状细胞,增强共刺激标记物、细胞因子和交叉呈递作用。在配制成 PPTEE + 微乳剂(ME)后,它提高了体内的免疫反应,促进了抗原特异性抗体和 CD8+ T 细胞的增殖。在肿瘤小鼠体内施用 PPTEE + ME 可诱导肿瘤明显消退,这与免疫抑制细胞的激活有关。这项研究凸显了高纯度奥氏拉布拉多来源β-葡聚糖(尤其是PPTEE)作为有前景的免疫佐剂的潜力,为推进癌症免疫疗法提供了新的途径。
Investigating the Immune-Stimulating Potential of β-Glucan from Aureobasidium pullulans in Cancer Immunotherapy.
β-glucan, a polysaccharide found in various sources, exhibits unique physicochemical properties, yet its high polymerization limits clinical applications because of its solubility. Addressing this limitation, we introduce PPTEE-glycan, a highly purified soluble β-1,3/1,6-glucan derived from Aureobasidium pullulans. The refined PPTEE-glycan demonstrated robust immune stimulation in vitro, activated dendritic cells, and enhanced co-stimulatory markers, cytokines, and cross-presentation. Formulated as a PPTEE + microemulsion (ME), it elevated immune responses in vivo, promoting antigen-specific antibodies and CD8+ T cell proliferation. Intratumoral administration of PPTEE + ME in tumor-bearing mice induced notable tumor regression, which was linked to the activation of immunosuppressive cells. This study highlights the potential of high-purity Aureobasidium pullulans-derived β-glucan, particularly PPTEE, as promising immune adjuvants, offering novel avenues for advancing cancer immunotherapy.
期刊介绍:
Biomolecules & Therapeutics (Biomolecules & Therapeutics) (Print ISSN 1976-9148, Online ISSN 2005-4483) is an international, peer-reviewed, open access journal that covers pharmacological and toxicological fields related to bioactive molecules and therapeutics. It was launched in 1993 as "The Journal of Applied Pharmacology (ISSN 1225-6110)", and renamed "Biomolecules & Therapeutics" (Biomol Ther: abbreviated form) in 2008 (Volume 16, No. 1). It is published bimonthly in January, March, May, July, September and November. All manuscripts should be creative, informative, and contribute to the development of new drugs. Articles in the following categories are published: review articles and research articles.